Ascentage Pharma Group International - American Depository Shares

Capital has been directed toward late‑stage development with pragmatic financing and BD. The January 2025 Nasdaq listing and July 2025 offshore placement strengthened liquidity to fund commercialization and global trials.

The Takeda option secured 100 million dollars upfront and creates a potential path to globalize olverembatinib with limited internal commercial build, which we view as high‑quality non‑dilutive capital if exercised.

Offsetting factors include ongoing dilution from equity raises and stock‑based awards, and reliance on milestone economics that are uncertain in timing and probability.